



CSAM Health Group AS

Quarterly Report Q1-23 12 May 2023 Emergency response and healthcare *niche software* The leading provider in the Nordics, growing across Europe and beyond

CSAM's software facilitates life-changing milestones

Vital solutions for 500 healthcare and emergency response organisations across 27 countries







Developing diversified and growing business areas








Note: YTD 2023

















Reported sales outside the Nordics increased to 14% vs 12% in Q1-22




Growing the EBITDA margin through BIB




Current BIB integration project portfolio



BIB history and the plan to reach 30% EBITDA margin



Team Task: From 5% EBITDA margin in Q1-23 to ~30% in Q3-23




Business Area breakdown

| Key figures per Business Area | Sales ⁽¹⁾ | EBITDA | Capex | Organic growth |
|----------------------------------|----------------------|--------|-------|-------------------|
| Connected Healthcare | 12.9 | -1 % | 2 % | 18 % |
| Health Analytics | 6.7 | 8 % | 0 % | 1 % |
| LIMS | 12.6 | -30 % | 16 % | -9 % |
| Medical Imaging | 7.4 | 14 % | 23 % | 11 % |
| Medication Management | 3.4 | 14 % | 0 % | -19 % |
| Public Safety | 45.5 | 13 % | 9 % | 15 % |
| Women & Children's Health | 11.6 | 13 % | 3 % | -7 % |

Comments


- Expect quarterly lumpiness in BA's as booked income is based on delivery milestones. Applies this quarter to:
 - LIMS
 - Medication Management
 - Women & Children's Health
- Connected Healthcare: Consultants on a temporary basis related to growth
- Health Analytics: Still in BIB integration mode

From Nordic to Pan-European - and beyond




FINANCIALS

CSAM's recurring software revenues are steadily increasing




Note: Quarterly revenue development recurring revenue LFQ (NOKm)


Favourable revenue mix




Cost improvements to continue throughout 2023



EBITDA margin will gradually move towards 30%



Net working capital development improving




Comments

• CSAM has a communicated NWC target of -10% or better

• When acquiring companies, it takes some time before CSAMs NWC policies are applied in the acquired companies, hence NWC development will vary.

CSAM investors per May 2023




Concluding remarks

- 1. Organic growth
- 2. Profitability
- 3. M&A high activity, but will remain disciplined
- 4. Decentralised and empowered organisation
- 5. Gradual improvements next quarters

Where we came from and where we are heading



Our ambitions remain



Current long term recurring revenues

Focus on specialised software for healthcare

Large underlying market with structural growth

2021

Subscribe to our newsletter

Subscribe to our news

First Name

Last Name


Email address

News Types

- Financial News
- General News

I have read and agree to the terms & conditions





Thank you!